Patent SG-11201806251W-A (SG)
Title: Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
Inventor: CZIBERE AKOS
IPC: A61K45/06
Filed: 2017-03-15
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/160990 Al 21 September 2017 (21.09.2017) WIPO I PCT 1111111111111101110101011111010111110 0111100110111011110110111111111110111111 (51) International Patent Classification: A61K 39/395 (2006.01) A61K 31/519 (2006.01) A61K 45/06 (2006.01) A61K 31/565 (2006.01) A61K 31/4196 (2006.01) (21) International Application Number: PCT/US2017/022517 (22) International Filing Date: 15 March 2017 (15.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/308,783 15 March 2016 (15.03.2016) 62/356,127 29 June 2016 (29.06.2016) 62/431,242 7 December 2016 (07.12.2016) (71) Applicant: MERRIMACK PHARMACEUTICALS, INC. [US/US]; One Kendall Square, Suite B7201, Cam- bridge, MA 02139 (US). (72) Inventors: CZIBERE, Akos; 67 Aquavia Road, Medford, MA 02155 (US). FINN, Gregory, J.; 1756 Beacon Street #3, Brookline, MA 02445 (US). ZHANG, Hong; 91 Gerry Road, Chestnut Hill, MA 02467 (US). (74) Agents: REMILLARD, Jane, E. et al.; Nelson Mullins Riley & Scarborough LLP, One Post Office Square, Bo- ston, MA 02109-2127 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (84) US US US W O 20 17 / 160990 Al (54) Title: METHODS FOR TREATING ER+, HER2-, HRG+ BREAST CANCER USING COMBINATION THERAPIES COM- PRISING AN ANTI-ERBB3 ANTIBODY (57) : Provided herein are compositions and methods for treating ER+, HER2- HRG+ breast cancer (e.g., metastatic ER+, HER2- breast cancer) in a patient by administering to the patient an anti-ErbB3 antibody seribantumab), a CDK4/6 inhibitor (e.g., (e.g., palbociclib), and an endocrine based therapy letrozole or fulvestrant) according to a particular clinical dosage regimen (e.g., (i.e., at a particular dose amount and according to a specific dosing schedule). Also provided herein are compositions and methods for treating ER+, HER2- HRG+ breast cancer (e.g., metastatic ER+, HER2- breast cancer) in a patient by administering to the patient an anti-ErbB3 antibody (e.g., seribantumab) and an endocrine based therapy (e.g., letrozole or fulvestrant) according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).